The invasive fungal infections market is expected to grow by 2034, owing to the approval of new agents such as Ibrexafungerp (Glaxosmithkline/SCYNEXIS), Fosmanogepix (Basilea Pharmaceutica), Olorofim (F901318) (Shionogi/F2G), Opelconazole (PC945) (Pulmocide), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with IFIs.
LAS VEGAS, Feb. 9, 2026 /PRNewswire/ — DelveInsight’s Invasive Fungal Infections Market Insights report includes a comprehensive understanding of current treatment practices, invasive fungal infections emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Invasive Fungal Infections Market Summary
Discover the new invasive fungal infections treatment @ https://www.delveinsight.com/sample-request/invasive-fungal-infections-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Invasive Fungal Infections Market
Invasive Fungal Infections Market Analysis
Invasive Fungal Infections Competitive Landscape
The IFIs pipeline possesses several candidates currentlyin mid- and late-stage developments to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including Ibrexafungerp (Glaxosmithkline/SCYNEXIS), Fosmanogepix (Basilea Pharmaceutica), Olorofim (F901318) (Shionogi/F2G ), Opelconazole (PC945) (Pulmocide), and others.
Glaxosmithkline/SCYNEXIS’ Ibrexafungerp is the first drug in a novel class of structurally unique glucan synthase inhibitors called triterpenoids. It exhibits broad-spectrum antifungal activity against diverse pathogens, including Candida, Aspergillus, Pneumocystis, dimorphic fungi, and mucorales, and is effective even against multidrug-resistant (MDR) and pan-resistant strains such as Candida auris. The drug is already approved for treating Vulvovaginal Candidiasis (VVC) and is currently being evaluated in a Phase III clinical trial (NCT05178862) for invasive candidiasis and other difficult-to-treat fungal infections.
Basilea Pharmaceutica’s Fosmanogepix is a first-in-class, broad-spectrum antifungal in clinical development that inhibits the fungal enzyme Glycosylphosphatidylinositol-anchored wall transfer Protein 1 (Gwt1), a critical component for cell wall integrity and fungal survival. This unique mechanism allows it to act against a wide range of pathogens, including Candida species (notably C. auris and azole-resistant strains), Aspergillus, Fusarium, Scedosporium, rare molds, and endemic fungi.
The anticipated launch of these emerging therapies are poised to transform the invasive fungal infections market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the invasive fungal infections market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the invasive fungal infections drugs market @ Invasive Fungal Infections Drugs
Recent Developments in the Invasive Fungal Infections Market
What are Invasive Fungal Infections?
Invasive fungal infections are serious diseases marked by the penetration of fungal pathogens into normally sterile areas of the body, such as deep tissues and vital organs, often resulting in prolonged illness and potentially fatal complications. These infections primarily occur in individuals with compromised immune systems, including those receiving chemotherapy, people living with HIV/AIDS, or organ transplant recipients on immunosuppressive drugs. The main causative agents include Candida species (notably Candida albicans, C. glabrata, C. tropicalis), Aspergillus species (especially Aspergillus fumigatus), Cryptococcus species, and various dimorphic fungi. Typically, these fungi are opportunistic organisms, normally harmless residents of the environment or human microbiota, that turn pathogenic when the host’s immune defenses are weakened.
Invasive Fungal Infections Epidemiology Segmentation
The invasive fungal infections epidemiology section provides insights into the historical and current invasive fungal infections patient pool and forecasted trends for the leading markets. Approximately, 90% of patients develop resistance to first-line antifungal therapy, necessitating therapy modification. Among these, nearly 30% also develop resistance to second-line agents, forcing switches within drug classes (e.g., azoles) or across classes (e.g., from azoles to echinocandins or polyenes).
The invasive fungal infections treatment market report proffers epidemiological analysis for the study period 2020-2034 in the leading markets, segmented into:
Scope of the Invasive Fungal Infections Market Report
Download the report to understand the factors driving the invasive fungal infections market @ Invasive Fungal Infections Market Analysis
Candidiasis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key candidiasis companies including Cidara Therapeutics, MATINAS BIOPHARMA HOLDINGS, ProFem GmbH, CelaCare Technologies, Inc., SCYNEXIS, NovaDigm Therapeutics, NovaBiotics Ltd, Stadius Biopharma, Mycovia Pharmaceuticals, ORYN THERAPEUTICS, Biocidium Biopharmaceuticals, Hyloris Pharmaceuticals, among others.
Candidiasis Clinical Trial Analysis
Candidiasis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key candidiasis companies, including Cidara Therapeutics, MATINAS BIOPHARMA HOLDINGS, ProFem GmbH, CelaCare Technologies, Inc., SCYNEXIS, NovaDigm Therapeutics, NovaBiotics Ltd, Stadius Biopharma, Mycovia Pharmaceuticals, ORYN THERAPEUTICS, Biocidium Biopharmaceuticals, Hyloris Pharmaceuticals, among others.
Invasive Pneumococcal Disease Market
Invasive Pneumococcal Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key invasive pneumococcal disease companies including Pfizer, Merck, Wyeth Pharmaceuticals, GlaxoSmithKline, Merck Sharp & Dohme Corp, Affinivax, Astellas Pharma, Vaxcyte, ImmunoBiology Ltd., Merck Sharp & Dohme Corp, EuBiologics, among others.
DHODH Inhibitors Market
DHODH Inhibitors Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key DHODH inhibitors companies, including Immunic Therapeutics, Jabez Bioscience, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
View original content:https://www.prnewswire.co.uk/news-releases/invasive-fungal-infections-market-to-witness-upsurge-in-growth-at-a-cagr-of-11-4-in-the-us-during-the-forecast-period-20252034-delveinsight-302682266.html
